Development and validation of a prediction model for 1-year all-cause rehospitalisation after discharge in patients with heart failure with preserved ejection fraction based on the systemic immune-inflammation index - Takeaways - MDSpire

Development and validation of a prediction model for 1-year all-cause rehospitalisation after discharge in patients with heart failure with preserved ejection fraction based on the systemic immune-inflammation index

  • By

  • Pan Chen

  • Xiaoyan Yin

  • Boshi Liu

  • Lei Ren

  • May 8, 2026

  • 0 min

Share

  • 1

    A predictive model for 1-year all-cause readmission in HFpEF patients was developed using the systemic immune-inflammation index and other clinical factors.

  • 2

    The study analyzed 312 HFpEF patients, with 218 in the training set and 94 in the validation set, after excluding 29 lost to follow-up.

  • 3

    Key predictors in the final model included LnSII, LnNT-proBNP, LnLp(a), GFR, and hypertension, demonstrating strong discrimination.

  • 4

    The model achieved an area under the curve of 0.8468 in the training cohort and 0.8302 in the validation cohort, indicating robust performance.

  • 5

    Calibration was acceptable, and decision curve analysis suggested potential clinical applicability, though external validation is needed.

Original Source(s)

Development and validation of a prediction model for 1-year all-cause rehospitalisation after discharge in patients with heart failure with preserved ejection fraction based on the systemic immune-inflammation index

  • by Pan Chen, Xiaoyan Yin, Boshi Liu, Lei Ren

  • May 8, 2026

Related Content

A Smarter Screen for Sleep Apnea Stimulation

A four-factor staging system stratified response rates from 90.9% to 37.5% in a retrospective cohort study, although the model showed only moderate discrimination (C statistic, 0.68) and requires external validation

Association Between Metabolic Clusters and Microbial Age in High-Risk Populations for Diabetes and Their Potential Impact on Cardiovascular Disease Risk: Cross-Sectional Observational Study

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.